EdgarLookup

Inhibikase Therapeutics, Inc. — Insider Transactions

Form 4 filings by directors, officers, and 10%+ shareholders

SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.

Overview All Filings Annual Quarterly Insiders
Insider Title Type Shares Price Value Owns After Date
SANDS FRANK M. Purchase 2,068,965 $1.45 $2,999,999 13,018,965 Nov 21, 2025
Munshi Amit Award / Grant 57,265 57,265 Feb 21, 2025
Bellini Roberto Purchase 1,460,000 $1.37 $2,000,200 1,460,000 Oct 21, 2024
Kush Arvind Purchase 145,000 $1.37 $198,650 145,000 Oct 21, 2024
Munshi Amit Purchase 365,000 $1.37 $500,050 365,000 Oct 21, 2024
Werner Milton H. President and CEO Purchase 5,000 $0.80 $4,000 5,335,433 Aug 16, 2022
Werner Milton H. President and CEO Purchase 5,000 $0.98 $4,900 5,330,433 May 27, 2022
Werner Milton H. President and CEO Purchase 10,000 $0.60 $6,000 5,325,433 May 20, 2022
FRATTAROLI JOSEPH Chief Financial Officer Purchase 3,948 $0.64 $2,527 48,091 May 19, 2022
Werner Milton H. President and CEO Option Exercise 21,853 $2.02 $44,143 5,315,433 Jan 3, 2022
Werner Milton H. President and CEO Purchase 1,100 $1.97 $2,167 23,589 Nov 17, 2021
Werner Milton H. President and CEO Option Exercise 21,853 $2.02 $44,143 5,293,580 Aug 17, 2021
Werner Milton H. President and CEO Tax Withholding 16,918 $4.59 $77,654 5,271,727 May 14, 2021
FRATTAROLI JOSEPH Chief Financial Officer C 44,143 $10.00 $441,430 44,143 Dec 28, 2020